Drug intelligence / Profile preview

iGC101

Development stage: Preclinical
Lead developer: JunCell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

iGC101 is a preclinical-stage mRNA-based Chimeric Antigen Receptor (CAR) Natural Killer (NK) cell therapy being developed by JunCell. This therapeutic approach involves the transient expression of CARs on NK cells using mRNA transfection, which is designed to enhance the cells' ability to target and eliminate solid tumor cells while potentially offering a safer profile compared to viral-based CAR therapies due to the non-integrative nature of mRNA. The specific target of the CAR in iGC101 is not publicly disclosed in the provided context, but the program is positioned for the treatment of various solid tumors.

Targets

Patient-specific tumor neoantigen-HLA complex

Beyond the preview

Go deeper on iGC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iGC101.

Explore the full profile